FilingReader Intelligence
Kwality Pharmaceuticals reports strong growth, biosimilar launch ahead
August 16, 2025 at 06:29 PM UTC•By FilingReader AI
Kwality Pharmaceuticals reported standalone revenue of ₹37,019.70 lakhs and profit after tax of ₹3,988.97 lakhs for FY 2024-25.
The company's biosimilar program is progressing, with commercialization of biological erythropoietin expected within the current financial year.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:KPL•Bombay Stock Exchange
News Alerts
Get instant email alerts when Kwality Pharmaceuticals publishes news
Free account required • Unsubscribe anytime